Session » Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Date: Friday, November 6, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0305

A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0314

Accuracy of Physical Examination to Detect Synovial and Extra-synovial Pathologies in Psoriatic Arthritis in Comparison to Ultrasonography

9:00AM-11:00AM: Abstract Number: 0336

Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe

9:00AM-11:00AM: Abstract Number: 0320

Assessment of Implementation of Treat to Target Concept Using Validated Composite Scores in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0317

Axial Involvement in Psoriatic Arthritis in a Comprehensive Rapid Diagnosis Program (Reuma-check PsA). Analysis of Its Characteristics

9:00AM-11:00AM: Abstract Number: 0306

Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

9:00AM-11:00AM: Abstract Number: 0343

Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0333

Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0334

Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 0324

Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials

9:00AM-11:00AM: Abstract Number: 0312

Dactylitis Is Associated with Greater Disease Severity, Ultrasound Synovitis, and Erosive Damage, in Very Early DMARD Naïve Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0308

Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study

9:00AM-11:00AM: Abstract Number: 0322

Development and Preliminary Validation of Smartphone Sensor-based Measurement Tools for Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0309

Diagnostic Delay in Psoriatic Arthritis: A Population Based Study

9:00AM-11:00AM: Abstract Number: 0326

Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe

9:00AM-11:00AM: Abstract Number: 0332

Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 0328

Healthcare Utilization and Costs Among Patients with Psoriatic Arthritis and Psoriasis in the United States – a Retrospective Study of Claims Data from 2009 to 2020

9:00AM-11:00AM: Abstract Number: 0329

Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0316

High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0338

Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0335

Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0339

Is Sex-adjusted Treatment in Early-PsA Justified?

9:00AM-11:00AM: Abstract Number: 0307

Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0341

Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity

9:00AM-11:00AM: Abstract Number: 0342

Multimorbidity Clusters in Psoriatic Arthritis: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 0330

Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors

9:00AM-11:00AM: Abstract Number: 0340

Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity

9:00AM-11:00AM: Abstract Number: 0321

Outcome Measures in Psoriatic Arthritis Registries Are Very Heterogeneous: A Systematic Literature Review of 27 Registries, or 16183 Patients

9:00AM-11:00AM: Abstract Number: 0318

Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 0323

Residual Symptoms in Patients with PsA Who Are in Very Low Disease Activity According to Physician Assessments

9:00AM-11:00AM: Abstract Number: 0337

Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function

9:00AM-11:00AM: Abstract Number: 0327

Skin Involvement in Psoriatic Arthritis (PsA) – The Incremental Impact of Psoriasis on Quality of Life, Disability and Work Productivity: Real-world Survey in US and Europe

9:00AM-11:00AM: Abstract Number: 0313

Swollen Joints but Not Tender Joints Are Associated with Ultrasound Power Doppler Synovitis in Very Early DMARD Naive Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0319

Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24

9:00AM-11:00AM: Abstract Number: 0325

The Impact of PsA Disease Control Status on Patient Treatment Satisfaction: Real-world Survey in US and Europe

9:00AM-11:00AM: Abstract Number: 0311

The Link Between Joints and Entheses in Psoriatic Arthritis: An Ultrasound Study Supporting the Synovio-entheseal Complex Theory

9:00AM-11:00AM: Abstract Number: 0310

The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report

9:00AM-11:00AM: Abstract Number: 0315

The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 0344

Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease

9:00AM-11:00AM: Abstract Number: 0331

Work Absenteeism and Disability Associated with Psoriatic Arthritis and Psoriasis in the United States – A Retrospective Study of Claims Data from 2009 to 2020

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].